Exploring the Future Through Ocular Gene Editing and Strategic Drug Delivery at Ophthalmic Drugs 2018
SMi’s 2nd annual Ophthalmic Drugs Conference returning to London, taking place at the Copthorne Tara Hotel in Kensington, on the 26th – 27th November 2018.
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.
Building on last year’s success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development and delivery. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs.The two-day event will also feature two interactive, half-day post-conference workshops on 28th November 2018, led by twoXAR and Aston University
This year’s agenda highlights include:
- Discover recent advances in the treatment of glaucoma
- Gain insight into the first FDA-approved gene therapy, developed for the treatment of inherited retinal dystrophy
- Discuss case studies on novel non-invasive and site-specific drug delivery strategies
- Examine the applications of artificial intelligence in drug discovery
- Explore use of biomarkers and surrogate end-points from a regulatory perspective
Chairs for 2018:
- Mitchell de long, Vice President, Chemistry, Aerie Pharmaceuticals
- Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen
Key Speakers:
- Majid Anderesi, Associate Group Clinical Director, Ophthalmology, Roche
- Caroline Barelle, CEO, Elasmogen
- Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim
- Daniel Chung, Clinical Ophthalmic Lead, Spark Therapeutics
- AnizGirach, Chief Medical Officer, Nightstar Therapeutics
- Peter Morgan-Warren, Medical Assessor, Licensing Division, MHRA
- David Silverman, Clinical Director, Ophthalmology, Roche
For those looking to attend, there is currently a £300 early-bird saving, ending June 29th.
Download the 2018 agenda online and see the full speaker line-up and presentations, as well as the attendee list from last year at: www.ophthalmicdrugs.com/pjpr
SMi presents the 2nd annual:
Ophthalmic Drugs 2018
Date: 26th – 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.ophthalmicdrugs.com/pjpr
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk